V
Volpara Health Technologies
Measurement solutions for breast composition in order to improve the health outcomes of women around the world
About Volpara Health Technologies
Volpara Health is a healthcare technology company specializing in breast health, leveraging artificial intelligence (AI) to enhance early detection of breast cancer. The company operates in the medical imaging and healthcare analytics market, serving breast imaging centers and healthcare providers globally. Volpara's core product is its Breast Health Platform, which integrates AI for clinical decision support, personalized detection strategies, and optimized program performance. This platform is clinically validated and trusted by top cancer screening centers, improving mammogram quality and reducing false positives. Volpara generates revenue through a subscription-based business model, offering its software as a service (SaaS) to healthcare facilities. The company aims to revolutionize breast cancer screening and care, ensuring better outcomes for patients through advanced technology and personalized care.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2009
- Headquarters
- Wellington, New Zealand
- Listing
- IPO 2016
- Sector
- Health Tech & Medtech
- Power Law
- Colt$25–100M revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
- UOUniversity of Oxford
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Volpara Health Technologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Volpara Health Technologies on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.